We are singularly focused on advancing aldoxorubicin by supplying the capital and operational expertise needed to bring it to patients sooner.
Learn about AldoxAt the end of 2022, co-founder Sid Sijbrandij was diagnosed with osteosarcoma and endured rounds of high-dose doxorubicin—nicknamed “the red devil” for its vivid color and punishing side-effects. When the drug stopped working for him, Sid resolved to make sure future patients wouldn’t face the same ordeal. Learning about aldoxorubicin—an investigational therapy designed to target tumors while sparing healthy tissue—suggested a better alternative, although his own treatment history meant it was no longer an option for him. Determined to speed that alternative to the clinic, he launched Gemini Therapeutics, motivated to help others avoid the hardship he experienced.